VectRx
Pre-clinical- Indications
- Pancreatic cancer
Company intelligence / Profile preview
NeoTherma Oncology
Wichita, Kansas, United Statesae.linkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has submitted an FDA IDE (Investigational Device Exemption) for its VectRx Thermal Oncology System to treat pancreatic cancer patients. The device has received FDA Breakthrough Device Designation within the Expedited Access Pathway for pancreatic cancer treatment. Preclinical animal studies have shown safety and effectiveness of RF-generated heat delivery for deep solid tumors.[4][5]
- Therapeutic areas
- Oncology
- Modalities
- Bioelectric deviceRadio frequency (RF) thermal treatment
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NeoTherma Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoTherma Oncology.